Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3212]

ASH 2011: New drug data for managing rare blood cancers and conditions

ASH 2011: New drug data for managing rare blood cancers and conditions

ASH 2011: Study of two sisters sheds light on lymphoma evolution

ASH 2011: Study of two sisters sheds light on lymphoma evolution

ASH 2011: Donor T-Cells results in excellent relapse-free survival

ASH 2011: Donor T-Cells results in excellent relapse-free survival

ASH 2011: Over-expression of TRAIL on donor T-cells enhances GVT and suppresses GVHD

ASH 2011: Over-expression of TRAIL on donor T-cells enhances GVT and suppresses GVHD

ASH 2011: Bruton’s tyrosine kinase inhibitor induces durable responses in relapsed leukaemia and lymphoma

ASH 2011: Bruton’s tyrosine kinase inhibitor induces durable responses in relapsed leukaemia and lymphoma

ASH 2011: Randomized phase II trial comparing GA101 with rituximab

ASH 2011: Randomized phase II trial comparing GA101 with rituximab

ASH 2011: Final analysis of a randomised comparison of ABVD chemotherapy with radiation therapy

ASH 2011: Final analysis of a randomised comparison of ABVD chemotherapy with radiation therapy

ASH 2011: Cereblon expression is required for the anti-myeloma activity of lenalidomide and pomalidomide

ASH 2011: Cereblon expression is required for the anti-myeloma activity of lenalidomide and pomalidomide

ASH 2011: B-cell depletion, remissions of malignancy, and cytokine-associated toxicity in a clinical trial of T-cells genetically-engineered to express an anti-CD19 chimeric antigen receptor

ASH 2011: B-cell depletion, remissions of malignancy, and cytokine-associated toxicity in a clinical trial of T...

ASH 2011: Novel chromosomal rearrangements and sequence mutations in high-risk ph-like acute lymphoblastic leukaemia

ASH 2011: Novel chromosomal rearrangements and sequence mutations in high-risk ph-like acute lymphoblastic...

More from ecancer